Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
16 hrs ago | TheStreet.com
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Here are three things that could send shares higher if they come to fruition. 1. Sales of Gilead's hepatitis C drugs don't drop Talk about a low bar for success.
A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.
Hedge fund manager, the inventor of "Magic Formula" Joel Greenblatt just reported his second quarter portfolio at Gotham Asset Management, LLC. He reshuffled his portfolio dramatically during the quarter, and bought Chicago Bridge & Iron Company, Delta Air Lines Inc, Towers Watson & Co, Gilead Sciences Inc, Monster Beverage Corp, Teradata Corp, ... (more)
Gilead Sciences CFO Robin L. Washington sold 33,556 shares of the company's stock on the open market in a transaction dated Thursday, August 14th.
Healthcare has been one of the hottest sectors over the last year and continues to find new highs.
The U.S. Centers for Disease Control and Prevention estimates there are 3.2 million Americans with chronic hepatitis C, 17,000 of whom will die this year as a result of the infection - a number that exceeds the annual deaths from HIV/AIDS in the U.S. Fortunately, Gilead Sciences produces a new breakthrough drug, Sovaldi, which has proved to cure 90 ... (more)
The company is engaged in discovering, producing and commercializing medicines to treat viral infections.
Gilead Sciences 's share price gapped up before the market opened on Friday after Cowen and Company raised their price target on the stock from $95.00 to $105.00, Analyst Ratings Net reports.
However, J.P. Morgan Securities raised its price target on JCP to $11 from $9, representing an unusually bullish forecast for the stock.
Today: Shares in Santa Clara equipment maker Applied Materials get a boost after it reports big jump in profit, improved sales forecast.
Investors are often deterred from investing in a stock when its price reaches an all-time high as it recently has in Gilead.
Its forward P/E is low relative to the market, thus incorporating caution about the sustainability of profits from its hepatitis C franchise.
An arbitration panel ruled Friday that the Foster City-based drug maker's hepatitis C blockbuster Sovaldi did not infringe a 2004 research deal that rival Roche had with Pharmasset Inc. Gilead , led by Chairman and CEO John Martin , bought Pharmasset in 2012 for $11 billion, landing the drug that would become Sovaldi.
Achillion Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naA ve genotype 1 chronic hepatitis C virus infection.
Updated: Thu Aug 21, 2014 10:08 am
Copyright © 2014 Topix LLC